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Policy & practice

Integrating tuberculosis and antimicrobial resistance control
programmes
Rumina Hasan,a Sadia Shakoor,a Johanna Hanefeldb & Mishal Khanb
Abstract Many low- and middle-income countries facing high levels of antimicrobial resistance, and the associated morbidity from
ineffective treatment, also have a high burden of tuberculosis. Over recent decades many countries have developed effective laboratory
and information systems for tuberculosis control. In this paper we describe how existing tuberculosis laboratory systems can be expanded
to accommodate antimicrobial resistance functions. We show how such expansion in services may benefit tuberculosis case-finding and
laboratory capacity through integration of laboratory services. We further summarize the synergies between high-level strategies on
tuberculosis and antimicrobial resistance control. These provide a potential platform for the integration of programmes and illustrate how
integration at the health-service delivery level for diagnostic services could occur in practice in a low- and middle-income setting. Many
potential mutual benefits of integration exist, in terms of accelerated scale-up of diagnostic testing towards rational use of antimicrobial drugs
as well as optimal use of resources and sharing of experience. Integration of vertical disease programmes with separate funding streams is
not without challenges, however, and we also discuss barriers to integration and identify opportunities and incentives to overcome these.

Introduction
Public health programmes that address the threats of antimicrobial resistance and of tuberculosis are major contributors
towards gains in global health.1,2 Unlike tuberculosis, antimicrobial resistance is not specifically mentioned in the health
targets of United Nations’ sustainable development goal 3.3
Both health issues, however, are encompassed in the overarching goal of ensuring healthy lives and promoting well-being
for all. The globally endorsed End Tuberculosis strategy4 and
Global Action Plan on Antimicrobial Resistance5 also agree on
universal health coverage and collaboration between diverse
stakeholders to achieve their objectives.
Despite potential synergies between them, antimicrobial
resistance and tuberculosis have until recently been positioned
as separate global health issues, and efforts aimed at controlling
both remain primarily vertical (disease-specific). Integration
across programme components has therefore been limited,
possibly leading to economic inefficiencies and suboptimal
service delivery. This is exemplified most clearly by the initial
decision to exclude Mycobacterium tuberculosis from the
global priority list of antibiotic-resistant bacteria,6 even though
estimates suggest that by the year 2050 drug resistant tuberculosis will be responsible for 2.6 million of the total 10 million
annual deaths associated with antimicrobial resistance.1,7 The
protests and concerns raised following this decision eventually
led to the inclusion of M. tuberculosis within the priority list,
highlighting the importance of integrating activities aimed
at addressing both health issues.8 A non-systematic review
of studies on integration of programmes on maternal and
child health, human immunodeficiency virus (HIV), sexually
transmitted infections and tuberculosis found that integration
increased uptake of services.9
Several antimicrobial agents used to treat tuberculosis are
also used for management of other infectious diseases. These
include fluoroquinolone antibiotics, which are used not only

for tuberculosis, but also for respiratory, urinary and enteric
infections. A systematic review and meta-analysis found that
use of fluoroquinolones in patients with respiratory infections
delayed the diagnosis of tuberculosis by nearly 2 weeks,10 thus
emphasizing the interdependence of antimicrobial resistance
and tuberculosis control efforts. Given such overlap, exposure
to antimicrobial drugs risks development of resistance in other
microorganisms.11
In this paper we summarize some opportunities and
challenges to integration of tuberculosis and antimicrobial
resistance programmes. We first summarize the synergies between high-level strategies on tuberculosis and antimicrobial
resistance control. These provide a potential platform for the
integration of programmes and illustrate how integration at
the health-service delivery level for diagnostic services could
occur in practice in a low and middle-income setting. We then
discuss barriers to integration and identify opportunities and
incentives to overcome these.

Synergies between programmes
Both the End Tuberculosis strategy and Global Action Plan
on Antimicrobial Resistance aim to improve health and control infectious diseases and, in particular, to limit the spread
of drug resistance. Therefore, despite differences in their
organizational structure and funding streams, integrating
certain activities will result in better use of resources and
increase the likelihood of achieving mutual goals. The End
Tuberculosis strategy already recognizes the importance of
collaboration with other initiatives and programmes;4 in
most countries, for example, tuberculosis programmes have
experience of collaboration with HIV programmes. Similarly,
many antimicrobial resistance programmes are being built
on a One Health approach,12 recognizing the importance of
engaging multiple partners, including those outside of the
human health sector.
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Partial integration between individual health programmes can be achieved
through linkages and collaborations,
but full integration requires integration
across the components of governance,
financing, service delivery and information systems.13 Integration between
tuberculosis control and antimicrobial
resistance programmes at the global
level could promote shared activities
within countries to achieve mutual
benefits for both programmes (Box 1).

Integration of laboratory
services
Over the last decade those involved in
tuberculosis control have developed
important new diagnostic tools and
established quality-assured laboratory
systems. As a result, detection of tuberculosis and in particular drug-resistant
tuberculosis has greatly increased. 2
Tuberculosis control planners have
experience in developing laboratory
systems towards better quality assurance
systems (such as in handling of sputum
smears), standardized record-keeping
and logistics support (including internet connectivity, reporting to national
programmes, supply chain management and coordination of laboratory
functions). These experiences could
be leveraged to strengthen diagnostic
laboratories involved in antimicrobial
resistance testing and surveillance. Indeed, the major initial focus of antimicrobial resistance control strategies is on
surveillance, with large investments now
being made to strengthen the often weak
surveillance of antimicrobial resistance
in low- and middle-income countries.14
A tuberculosis laboratory network
generally has a tiered structure,15 with
microscopy at the basic level, mycobacterial culture at the intermediate level,
and culture as well as drug sensitivity testing at the reference laboratory
level. Peripheral laboratories can offer
point-of-care tests that will help to
decrease antibiotic misuse by establishing when diseases have a viral cause.
At the intermediate level, laboratories
can share culture and antibiotic susceptibility testing capacities to provide
public health facilities with appropriate
antimicrobial resistance diagnostics.
Reference laboratories can contribute to
confirmation of bacterial resistance and
to surveillance for emerging resistance
mechanisms in pathogens. Laborato-

Box 1. Benefits of integration between programmes for tuberculosis control and
antimicrobial resistance
• Efficient use of resources currently allocated to separate tuberculosis control and
antimicrobial resistance programmes towards coordinated prevention and control strategies.
• Sharing of expertise, local experience and existing resources, such as staff and health
facilities, to enhance outcomes for both tuberculosis control and antimicrobial resistance
programmes.
• Development of synergistic technical packages covering clinical guidelines, diagnostic
pathways and tools, infection control and prevention, and evidence-based priority
interventions. These could work towards controlling resistance in the Mycobacterium
tuberculosis complex as well as bacteria in the global list of antibiotic-resistant priority
pathogens.6
• Greater advocacy and political attention for both tuberculosis and antimicrobial resistance.
Collaboration could intensify efforts towards improving the quality of care delivered by
informal health-care providers, regulating the pharmaceutical industry and controlling the
use of growth promoters in the veterinary industry.
• Reduced reliance on external resources, through integrating tuberculosis control and
antimicrobial resistance programmes within the national structures of high-burden
countries. In this way common goals would be safeguarded through a strengthened
oversight mechanism.

ries in the tuberculosis network have
well-established quality management
systems and biomedical and biosafety
infrastructures and, by using the same
facilities for antimicrobial resistance,
can bypass the need to create expensive
systems in new laboratories dedicated
to antimicrobial resistance.
Such a structure lends itself well to
close cooperation and integration with
antimicrobial resistance programmes.
Several diagnostic tools currently in use
for diagnosis of antimicrobial resistance,
as well as existing infrastructure and
human resources, could be adapted to
facilitate the integration of services, and
delivered in accordance with the level
and expertise available at the relevant
tuberculosis laboratories (Fig. 1). In
remote areas where laboratory access
for diagnosis of infectious diseases is
limited, services provided by the most
basic tuberculosis microscopy centres
could be expanded to include pointof-care testing for common infections.
Some examples of point-of-care tests
that could be incorporated into existing tuberculosis diagnostic services
include malaria diagnosis, microscopy
or dipstick testing for urinary tract
infections as well as pneumococcal and
Legionella antigen tests. This approach
would be strengthened when combined
with referral of specimens for culture
and sensitivity testing and initiation of
appropriate treatment to control further
spread of resistant organisms. Recently,
rapid molecular tests for tuberculosis
are being added, particularly at the
intermediate and reference levels, but
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in some cases also at the basic laboratory level. This system is underpinned
by logistics support and greater efforts
to expand connectivity for reporting
and monitoring within the network. At
the international level, the tuberculosis
laboratory network is supported by several supranational reference laboratories
that provide training and on-the-ground
assistance and advice as required.
Increasing the breadth of services
provided by tuberculosis laboratories
could be used to strengthen antimicrobial resistance diagnostic testing
and surveillance. Currently, one of
the most widely used rapid molecular
test for detection of M. tuberculosis is
Xpert® MTB-RIF (Cepheid, Sunnyvale,
United States of America). The Xpert®
technology, however, could also be used
for the rapid diagnosis of several other
bacterial and viral infections. The repertoire of infectious disease diagnostics
is constantly expanding, based on new
technologies including microfluidics16
and film arrays.17,18 These could easily
be placed in integrated intermediate
level laboratories, with a wider test
menu towards guided antimicrobial
therapy. Finally, many of the supranational tuberculosis reference laboratories have already confirmed that they
could expand susceptibility testing for
other pathogens if funding were available.19 Their expanded role could be
leveraged as an opportunity towards
self-sustainability by adding to the core
competency of each laboratory and
also an expanded role for tuberculosis
laboratory networks.
195
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Fig. 1. Diagnostic tools currently in use at different levels of tuberculosis diagnostic facilities
Local laboratories
Tuberculosis services:
• Smear microscopy
• Xpert® MTB/RIF system for tuberculosis diagnosis
• Electronic reporting systems
Potential antimicrobial resistance services:
• Xpert® system for diagnosis of other infections
(enterovirus; Clostridium difficile; hepatitis B virus;
hepatitis C virus; human immunodeficiency virus;
Chlamydia trachomatis and Neisseria gonorrhoeae;
influenza and respiratory syncytial virus)
• Xpert® for drug resistance testing (carbapenem-resistant Enterobacteriaceae; methicillin-resistant Staphylococcus aureus)
• Point-of-care tests for detection of infections
(FebriDx® Myxovirus resistance protein A and
ImmunoPoC;™ urine dipstick; immunochromatographic test for malaria; urinary antigen tests e.g.
pneumococcus, Legionella)

Intermediate laboratories
Tuberculosis services:
• Mycobacterium tuberculosis identification and
drug susceptibility testing
• Liquid drug sensitivity testing (mycobacteria
growth indicator tube)
• Line-probe assays

Potential antimicrobial resistance services:
• Blood automatic cultures (mini-BACTEC™);
sputum cultures for bacterial pneumonia
• Drug susceptibility testing (disk diffusion; VITEK®
or Microscan® or agar dilution; Etest® minimum
inhibitory concentration tests).
• Line-probe assays (Helicobacter pylori)
• Film-array tests (meningitis; respiratory and
gastrointestinal infections; blood cultures).

Reference laboratories
Tuberculosis services:
• Mycobacterium tuberculosis and nontuberculous
mycobacteria identification and drug susceptibility
testing
• Minimum inhibitory concentration testing
• Possibly genotyping or sequencing services

Potential antimicrobial resistance services:
• Organism identification by matrix-assisted laser
desorption-ionization time-of-flight mass
spectrometry and sequencing
• Reference minimum inhibitory concentration
testing
• Population analysis profiling

Better quality management systems, biomedical engineering capacity and biosafety infrastructure
Notes: The following are trademark technologies: Xpert® (Cepheid, Sunnyvale, United States of America; USA); FebriDx® (RPS Diagnostics; Sarasota, USA);
ImmunoPoC (MeMed Diagnostics, Israel); BACTEC (Becton Dickinson Diagnostics, Sparks, USA); VITEK® (bioMèrieux, Marcy-l’Étoile, France); Microscan® (Beckman
Coulter, Brea, USA); Etest® (bioMérieux, Marcy l’Etoile, France).

Another advantage is that the
broader infrastructure could be shared
between tuberculosis and antimicrobial
resistance programmes. Low-resource
settings face infrastructure challenges
to providing laboratory services. These
include shortages of trained laboratory
staff; lack of access to biomedical technical support;20 problems with installing,
validating, certifying and servicing
laboratory equipment; difficulties in
specimen transport; 21 difficulties in
data connectivity and management;
and challenges to maintaining biosafety
levels.22,23 While laboratory networks can
be resource-intensive and expensive to
run, they do lend themselves to serving
more than one health programme, allowing for optimal use of resources. For
example, establishment of an efficient
and far-reaching specimen referral network has been explored by investigators
in Ethiopia and Uganda, and shown
to be effective for multiple diseases,
including tuberculosis, HIV and hepatitis.21,24 Therefore, establishing shared
laboratory spaces, equipment and supplies, human resources and transport
systems would be mutually beneficial
to both tuberculosis and antimicrobial
resistance programmes and improve
universal access to diagnostics for the
population served.
196

Benefits of integrated
services
Integration of certain services in joint
laboratories could have benefits for
both tuberculosis and antimicrobial
resistance programmes. In low-resource
settings, expanding the scope of tests
within the existing tuberculosis laboratory network would increase patients’
access to diagnostics and encourage
rational use of antimicrobials. A recent
study on the impact of rapid diagnostic
tests for malaria in Africa and Asia
demonstrated that while rapid diagnosis reduced antimalarial drug use,
it also resulted in over-prescription of
antimicrobial agents.25 This highlights
the importance of not only enhancing
access to diagnostics, but also coordinating between disease-specific laboratory
networks and antimicrobial resistance
control programmes.
Integration will also enhance the
capacity of the tuberculosis laboratory
network, enabling the facilities and staff
to function beyond a single disease area,
and thereby serve a larger population of
patients. Broadening the patient population served by joint laboratories for tuberculosis and antimicrobial resistance
may also help to address the challenge of
low research and development funding

for tuberculosis diagnostics.26 As tuberculosis progresses towards elimination,
for-profit companies see limited scope
for financial returns on developing new
diagnostics for the disease. Investing in
diagnostics may be more attractive if
companies are able to cater to a larger
population with emerging diseases of
various etiologies, For example, industry
reports estimate that the market value
of diagnostics for infectious diseases
was worth 14.45 billion United States
dollars (US$) in 2016 and expected to
reach US$ 21.13 billion by 2021, with
the global worth of point-of-care diagnostics expected to reach US$ 1.9 billion
by 2025.27,28 With sufficient investment
in research and development, there
are opportunities for advancements in
laboratory medicine.
Many of the new tests being developed (including those for tuberculosis)
are of low complexity and performed
near the patient or at the point of
care,29 which is more convenient and
less costly for patients. The focus on
patient-centred approaches has also led
to the development of multiplex devices
designed to rapidly detect a variety of
bacterial, viral or fungal pathogens in
a single test.30 Currently many of these
technologies are of moderate complexity, requiring technical expertise that
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make them more suitable for intermediate or referral laboratories. Developments are underway, however, to make
such tests more affordable and to bring
them nearer to the point of care.
Newer, more expensive antibiotics
are being developed to replace those
made redundant due to high levels of
drug resistance. From the perspective of
an antimicrobial resistance programme
these developments will also increase
the need to improve access to effective
diagnostic tools to rule out differential
diagnoses.

Barriers to integration
A longstanding challenge is how to integrate individual vertical disease control
programmes with other vertical programmes and into primary health-care
services.31,32 Concerns about the effects
of integration on disease-specific funding and on human resources are common across many vertical programmes,
such as those for tuberculosis, malaria
and HIV.33 In the case of tuberculosis
and antimicrobial resistance, challenges
to integration may arise because powerful stakeholders (such as the Global
Fund to Fight AIDS, Tuberculosis and
Malaria for tuberculosis and the Global
Health Security Agenda focused on
antibiotic resistance) largely operate
independently of each other. Increasing
integration between programmes would,
by definition, require some relinquishing of disease-specific resources to a
common fund. The efficiencies achieved
from joint service delivery would also
likely result in job losses if human resource posts are merged, for example
among laboratory staff who can perform
diagnosis for both antimicrobial resistance and tuberculosis, and this could
be a source of conflict.
With different funding and accountability systems, the specific targets and
institutional structures of programmes
at the country level are also likely to be
different. Coordination and communication across national tuberculosis
control programmes, surveillance agencies and laboratory services departments will be essential. This will require
governance structures at the global and
national levels so as to better integrate
activities between programmes. Vertical
programmes often work towards very
focused targets. 34 Therefore, ensuring shared responsibility for mutually
beneficial disease control targets, such

as the number of symptomatic patients
receiving point-of-care testing or the
costs of diagnosis of patients, would
be important. Developing integrated
targets may work as one of the mechanisms to incentivize collaboration and
integration of services. A study from
India illustrated how a vertical disease
control programme with an explicit
policy of strengthening local health
systems helped to facilitate integration
of vertical programmes.35
Technical guidelines for diagnostic and antimicrobial stewardship will
need to be redesigned, despite possible
differences of opinion between diseasespecific technical experts.36,37 Currently,
tuberculosis laboratories embedded
within a well-structured vertical programme have clear policies and guidelines for testing, interpreting results
and treating patients. If tuberculosis
laboratory services are to be expanded,
guidelines on the use of diagnostics, information reporting protocols and management structures need to be updated.
Such integration will require acceptance
of new roles and new ways of working
by the staff in laboratory systems. It
will also create opportunities for accessing a larger patient population with
a wider spectrum of infections, along
with engaging health-care providers
from various specialties and government
bodies from different sectors. This can
only be achieved through coordinated
planning by antimicrobial resistance and
tuberculosis control programmes at the
country level; for example, to include
managing the expanded remit of staff
and their training in the use of a wider
set of technologies.

Conclusions
Integration of the nascent antimicrobial
resistance programmes within the well
established vertical disease control programmes is currently limited. This results in missed opportunities for greater
efficiency and better patient-centred
care. The World Health Organization
has highlighted gaps in coordination
of information management systems in
antimicrobial resistance programmes,
such as for electronic reporting and tools
for standardized surveillance.38
Given the shift from conventional
diagnostic tools to newer point-ofcare tests and the large investments in
antimicrobial resistance surveillance,14
we need to review the current role of
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diagnostic laboratories associated with
disease-specific programmes. As newer
multiplex point-of-care tests become
increasingly available, the concept of
programmes limited to diagnosis of a
single disease will require rethinking.
We argue that the tuberculosis laboratory system, with its strong microbiology
expertise and infrastructure, is particularly well placed to contribute towards
antimicrobial resistance control. Nevertheless, integration of disease-specific
programmes, which are not unique to
tuberculosis, also faces longstanding
barriers.
Many potential mutual benefits of
integration exist, in terms of accelerated
scale-up of diagnostic testing towards
rational use of antimicrobial drugs as
well as optimal use of resources. To
scale-up activities, it would be prudent
for governments to build on the existing regulatory frameworks, surveillance
systems, infection control systems,
laboratory infrastructure and human
resources that are already in place to
manage tuberculosis.19 Diagnostic tools,
logistics and technologies for sharing
data can be used to link programmes
at the country level towards a stronger
programme to control antimicrobial
resistance including in tuberculosis.
Not only would antimicrobial resistance
programmes gain from the tuberculosis
laboratory system, but tuberculosis
programmes themselves would benefit
from the political attention and funding currently being directed towards
antimicrobial resistance.
In addition to the focus on budgets
and resources, combined or integrated
inter-programme activities bring other
advantages. The main goal in partnerships in public health has been ensuring
the future sustainability of programmes.
By forging a partnership between antimicrobial resistance and tuberculosis
control programmes within countries’
governing structures, common goals
will be safeguarded through a strengthened oversight mechanism. Moreover,
programme integration presents opportunities to direct the focus of policymakers towards the issue of antimicrobial resistance, which has so far met
with limited success.39 Advocacy efforts
to influence pharmaceutical regulation,
formulary restrictions and use of growth
promoters in the veterinary industry
could be intensified. Public health messages released by control programmes
are useful catalysts for behavioural
197
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change in communities. Reinforcement
of such messages from tuberculosis
clinics, as well as hospitals and clinics
involved in antimicrobial resistance

control efforts, is likely to lead to faster
and more durable changes in antibiotic
use, attitudes to infection prevention
and general health awareness. ■
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ملخص

دمج برامج مكافحة مرض السل ومقاومة مضادات امليكروبات

 وقد ساهم ذلك يف تقديم منصة.مكافحة مضادات امليكروبات
حمتملة لدمج الربامج وتوضيح إمكانية التطبيق العميل للدمج
عىل مستوى تقديم اخلدمات الصحية للخدمات التشخيصية
 وتوجد العديد من املنافع.يف بيئة ذات دخل منخفض ومتوسط
املتبادلة املحتملة للدمج وذلك من حيث ترسيع وترية التوسع يف
نطاق االختبارات التشخيصية نحو االستخدام الرشيد للعقاقري
ً املضادة للميكروبات
فضل عن االستخدام األمثل للموارد وتبادل
 إال أن دمج الربامج الرأسية ملكافحة املرض مع قنوات،اخلربات
 وقد قمنا،التمويل املنفصلة ليس باألمر الذي خيلو من التحديات
كذلك بمناقشة عوائق الدمج ومتييز الفرص واحلوافر للتغلب عىل
.األمر

تعاين العديد من البلدان منخفضة ومتوسطة الدخل – والتي تواجه
 واألمراض،مستويات مرتفعة من مقاومة مضادات امليكروبات
املصاحبة الناجتة عن العالج غري الفعال – من معدالت مرتفعة
 وعىل مدى العقود األخرية قامت العديد.لإلصابة بمرض السل
من البلدان بتطوير أنظمة خمتربات ومعلومات فعالة ملكافحة
 ونصف يف هذا التقرير كيفية توسيع أنظمة املختربات.مرض السل
.املوجودة لتستوعب وظائف مقاومة مضادات امليكروبات
ونوضح كيف أن هذا التوسع يف اخلدمات قد يفيد يف الكشف عن
حاالت اإلصابة بمرض السل ويف القدرات املختربية من خالل
 وقد قمنا كذلك بتلخيص أوجه التآزر.دمج خدمات املختربات
بني االسرتاتيجيات رفيعة املستوى املتبعة مع مرض السل وبني

摘要
整合结核病与抗菌素耐药性控制方案
许多中低收入国家面临着高水平的抗菌素耐药性，由
于治疗效果不佳而造成的相关并发症，以及较高的结
核病负担。近几十年来，许多国家建立了有效的结核
病控制实验室和信息系统。本文中，我们描述如何扩
大现有的结核病实验室系统，以适应抗菌素的耐药功
能。我们展示了如何通过实验室服务的整合来扩大服
务范围，从而有利于结核病病例发现与实验室检测能
力。我们进一步总结了结核病与抗菌素耐药性控制高

层战略之间的协同作用。这些为方案的整合提供一个
潜在的平台，并且说明如何在低收入和中等收入地区
通过实践在医疗诊断服务提供层面进行整合。一体化
存在着许多潜在的互惠利益，包括加速推广合理使用
抗菌药物的诊断检测，以及优化利用资源和分享经验。
纵向疾病方案与单独资金流的整合并非没有挑战，然
而，我们还讨论了整合所面临的障碍，并找出克服这
些障碍的机会和激励措施。

Résumé
Intégration des programmes de lutte contre la tuberculose et contre la résistance aux antimicrobiens
De nombreux pays à revenu faible et intermédiaire qui sont confrontés à
une forte résistance aux antimicrobiens ainsi qu’à la morbidité associée,
due à l’inefficacité des traitements, sont aussi fortement touchés
par la tuberculose. Ces dernières décennies, de nombreux pays ont
mis au point des systèmes efficaces d’information et de laboratoire
afin de combattre la tuberculose. Dans cet article, nous décrivons
la manière dont les systèmes existants des laboratoires spécialisés
dans la tuberculose peuvent être élargis afin d’intégrer des fonctions
applicables à la résistance aux antimicrobiens. Nous montrons comment
cet élargissement des services pourrait contribuer au dépistage de la
tuberculose et aux capacités des laboratoires par l’intégration de services
de laboratoire. Nous faisons par ailleurs le point sur les synergies entre les
stratégies de haut niveau sur la tuberculose et la lutte contre la résistance

aux antimicrobiens. Celles-ci offrent des possibilités pour l’intégration
de programmes et illustrent la manière dont l’intégration au niveau de
la prestation des services de diagnostic pourrait se faire en pratique
dans les régions à revenu faible et intermédiaire. L’intégration pourrait
apporter de nombreux bénéfices mutuels, comme l’expansion plus
rapide des tests de diagnostic en vue d’une utilisation rationnelle des
médicaments antimicrobiens, d’une utilisation optimale des ressources
et d’un partage d’expérience. L’intégration de programmes verticaux de
lutte contre les maladies, qui ont des sources de financement différentes,
n’est cependant pas chose simple. Nous évoquons également les
obstacles à cette intégration ainsi que les perspectives et les mesures
incitatives pour les surmonter.

Резюме
Интеграция программ по борьбе с туберкулезом и устойчивостью к противомикробным препаратам
Многие страны с низким и средним уровнем дохода, столкнувшиеся
с высоким уровнем устойчивости к противомикробным
препаратам и связанной с ней распространенностью случаев
неэффективности лечения, помимо этого, имеют высокую
заболеваемость туберкулезом. За последние десятилетия во
198

многих странах были разработаны эффективные лабораторные
и информационные системы борьбы с туберкулезом. В этой
статье мы описываем, как существующие лабораторные системы
для диагностики туберкулеза могут быть расширены путем
включения методов определения лекарственной устойчивости
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к противомикробным препаратам. Мы демонстрируем, как
такое расширение сферы обслуживания может способствовать
выявлению случаев туберкулеза и укреплению лабораторного
потенциала за счет интеграции лабораторных услуг. Далее мы
подводим итоги синергии между стратегиями высокого уровня
по борьбе с туберкулезом и устойчивостью к противомикробным
препаратам. Они обеспечивают потенциальную платформу
для интеграции программ и иллюстрируют, каким образом на
практике в условиях низкого и среднего уровня дохода можно
было бы обеспечить интеграцию на уровне предоставления

медицинских услуг для диагностических служб. Существует
много аспектов потенциальной взаимной выгоды от интеграции
с точки зрения ускоренного расширения диагностического
тестирования в направлении рационального использования
противомикробных препаратов, а также оптимального
использования ресурсов и обмена опытом. Однако интеграция
вертикальных программ борьбы с заболеваниями с раздельными
потоками финансирования не лишена проблем, поэтому мы
также обсуждаем препятствия на пути интеграции и выявляем
возможности и стимулы для их преодоления.

Resumen
Integración de los programas de tuberculosis y control de resistencia a los antimicrobianos
Muchos países de ingresos bajos y medianos que enfrentan altos niveles
de resistencia a los antimicrobianos, así como la morbilidad asociada
por un tratamiento ineficaz, también presentan una alta incidencia de
tuberculosis. En las últimas décadas, muchos países han desarrollado
sistemas efectivos de laboratorio e información para el control de la
tuberculosis. En este documento describimos cómo los sistemas de
laboratorio de tuberculosis existentes pueden ampliarse para dar cabida
a las funciones de resistencia a los antimicrobianos. Mostramos cómo
dicha expansión en los servicios puede beneficiar la búsqueda de casos
de tuberculosis y la capacidad de laboratorio a través de la integración de
los servicios de laboratorio. Resumimos las sinergias entre las estrategias
de alto nivel sobre la tuberculosis y el control de la resistencia a los

antimicrobianos. Estos proporcionan una plataforma potencial para la
integración de programas e ilustran cómo la integración en el nivel de
prestación de servicios de salud para los servicios de diagnóstico podría
ocurrir en la práctica en un entorno de ingresos bajos y medianos. Existen
muchos beneficios mutuos potenciales de la integración, en términos de
una mejora acelerada de las pruebas de diagnóstico hacia el uso racional
de los medicamentos antimicrobianos, así como el uso óptimo de los
recursos y el intercambio de experiencias. Sin embargo, la integración
de programas de enfermedades verticales con flujos de financiación
separados no está exenta de desafíos, y también examinamos los
obstáculos a la integración e identificamos oportunidades e incentivos
para superarlas.
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